Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for... see more

Recent & Breaking News (NDAQ:ALNY)

Alnylam Initiates DISCOVERY, a Screening Study Examining the Prevalence of Transthyretin (TTR) Mutations in Patients Suspected of Having Cardiac Amyloidosis

Business Wire September 24, 2014

Alnylam to Webcast Presentation at 21st Annual NewsMakers in the Biotech Industry Conference

Business Wire September 19, 2014

Alnylam Presents New Pre-Clinical Data with ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases

Business Wire September 16, 2014

Alnylam Strengthens Management Team with New Key Appointments

Business Wire September 15, 2014

Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen (AGT) for the Treatment of Hypertensive Disorders of Pregnancy (HDP), Including Preeclampsia

Business Wire September 12, 2014

Alnylam to Webcast Presentation at Morgan Stanley Global Healthcare Conference

Business Wire September 3, 2014

Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering RNAi-Mediating, Double-Stranded Molecules of 19 to 52 Nucleotides in Length

Business Wire August 27, 2014

Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering RNAi-Mediating Double-Stranded Molecules Comprising Up to 25 Base Pairs

Business Wire August 20, 2014

Alnylam Pharmaceuticals Reports Second Quarter 2014 Financial Results and Highlights Recent Period Activities

Business Wire August 7, 2014

Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia

Business Wire August 7, 2014

Alnylam to Webcast Conference Call Discussing Second Quarter 2014 Financial Results

Business Wire July 31, 2014

Alnylam to Host Additional Events in "RNAi Roundtable" Webcast Series

Business Wire July 29, 2014

BIOPHARMA INDUSTRY LEADER AMY SCHULMAN JOINS POLARIS PARTNERS

GlobeNewswire July 29, 2014

Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics

Business Wire July 22, 2014

What RXi Pharmaceuticals' Move to the Russell Microcap Index Means

Accesswire July 9, 2014

Alnylam to Host "RNAi Roundtable" Webcast Series

Business Wire July 7, 2014

Alnylam Elects Amy Schulman to its Board of Directors

Business Wire July 2, 2014

Alnylam Added to Russell 1000 Index as a Member of the Large-Cap Segment of the U.S. Equity Universe

Business Wire June 30, 2014

Investing in the Best Canadian Biotech Stocks

Equities.com June 23, 2014

Alnylam and The Alpha-1 Project (TAP) Form Collaboration for Advancement of ALN-AAT, an RNAi Therapeutic in Development for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease

Business Wire June 19, 2014